Phar­ma com­pa­nies soft­en tone on full IRA im­pact

De­spite the phar­ma­ceu­ti­cal in­dus­try’s heavy crit­i­cism of the In­fla­tion Re­duc­tion Act, John­son & John­son, Pfiz­er and Bris­tol My­ers Squibb re­cent­ly down­played the leg­is­la­tion’s over­all im­pact on busi­ness in first-quar­ter earn­ings calls.

All three com­pa­nies voiced ear­ly op­po­si­tion to the IRA, liken­ing Medicare ne­go­ti­a­tions to price set­ting and ar­gu­ing that the law is a threat to in­no­va­tion. J&J’s ex­ec­u­tive VP Jen­nifer Taubert re­in­forced that stance in an April call with in­vestors. But she al­so not­ed that J&J’s prod­ucts cur­rent­ly un­der ne­go­ti­a­tion — Xarel­to, Ste­lara and Im­bru­vi­ca — “are not our growth dri­vers for the fu­ture.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER